On Wednesday, US-based pharmaceutical company Pfizer Inc. announced that it was planning to start an immunogenicity and safety study in the month of August for the evaluation of an updated version of its coronavirus vaccine specifically targeted against the highly contagious Delta variant.
The company added that the Delta variant was the most transmissible worldwide with a representation of approximately 83% of sequenced COVID-19 infections in the US alone.
”We continue to believe it is likely that a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection, and studies are underway to evaluate the safety and immunogenicity of a third dose”, it added.
Furthermore, company said in its quarterly earnings update on July 28 that it expects to have safety and immunogenicity data to support the US’ EUA for 5 to 11 year old children by September end.
The firm continued, “The full dataset from this study, which will be required to support licensure in this age group, is expected by the end of 2021.” It will be submitting similar data packages to support EUA and licensure in children aged 6 months to 5 years.
Pfizer reported unexpected profits and revenues for the second quarter alongside raising its full-year outlook on the powerful performance, which includes its sales of COVID-19 vaccine.
